◼ Archived
Business
Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal
Novartis strikes a massive licensing agreement worth up to $7.8 billion with China-based biotech firm Abogen.
3 trends tracked about this subject — the full history, oldest to newest below.
Novartis strikes a massive licensing agreement worth up to $7.8 billion with China-based biotech firm Abogen.
Novartis secures the rights to Abogen’s mRNA T cell engager in a massive $575 million upfront transaction.
Novartis has agreed to a massive new mRNA drug deal with Chinese startup Abogen worth up to $7.8 billion.